High materiality7/10
Zymeworks price target raised to $31 from $28 at Truist
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Truist raises ZYME target to $31 from $28. Current price is $26.45. Upside about 17%, signaling a bullish setup.
- Target vs price: $31 vs $26.45; upside ~17%.
- Analyst: Truist.
Key facts
- 01
Target: $31
- 02
Posted price: $26.45
- 03
Analyst firm: Truist Financial
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.